Developer of new drugs from botanical sources, especially anti-cancer and anti-atherosclerosis.
Lead drug is Antroquinonol, derived from Antrodia camphorata, a unique mushroom of Taiwan. IND status granted by US FDA in 2010, with Orphan Drug Designation granted in 2015.
Company has started a fermentation databank with major academic institutions in Taiwan providing fungus strains. Currently, 4000 fungus strains have been screened and stored in this databank.
Developer of botanically-derived drugs, also some health food products
First drug development company listed on the Taiwan stock market, back in 2008.
Member of the Maywufa Group, involved in health products, drug distribution, etc.
Built Taiwan’s first GMP sterile botanical drug manufacturing facility in compliance with PIC/S and FDA regulations.
Success story is ‘PG2’ lyophilized injection, approved by the TFDA for fatigue in cancer patients, and currently undergoing FDA Phase II trial for the same.
Other drugs in the pipeline include:
PHN131 (for moderate to severe pain)
PHN014 (for acute ischemia stroke)
PHN031 (for osteoporosis prevention)
PHN033 (for diabetic nephropathy treatment)
PHN015 (for hemorrhage stroke)
PHN013 (for idiopathic thrombocytopenic purpura (ITP))
PHDC-01 (stem cell treatment for bone growth)
PHDC-02 (stem cell treatment for cartilage growth)
Pharmaceuticals, new drugs, botanical drugs, nutrition and healthfood products. PIC/s GMP, ISO 9001, ISO 17025, ISO 14001, ISO 22000, and OHSAS 18001 pharmaceutical company in Taiwan
TCM concentrated herbal extracts, formulas and single herbs, over-the-counter products and also g/BRM botanical reference herbs.